Dr. Worthington is a Staff Psychiatrist in the Clinical Psychopharmacology Unit at the Massachusetts General Hospital, and
Instructor in Psychiatry at Harvard Medical School. He received his M.D. from Georgetown University School of Medicine in
Washington, D.C., completed his residency at the University of North Carolina Hospitals in Chapel Hill, N.C. and did a research
fellowship in Clinical Psychopharmacology at the Massachusetts General Hospital.
Currently he is an investigator on several
National Institutes of Mental Health studies involving the course of treatment-refractory panic disorder, treatment-resistant
depression, and the predication of outcome during antidepressant discontinuation. He is also an investigator in numerous phase
II and phase III clinical trials sponsored by several pharmaceutical companies. He has published over 110 articles, reviews
and posters and he lectures in national and international forums. His areas of clinical interest include the effects of alcohol
and substance use on mood and anxiety disorders, acute and long-term treatment plans of patients with panic disorder and depression,
development of novel pharmacologic agents for mood and anxiety disorders, and uses of combined cognitive-behavioral and pharmacologic
therapies for treatment-refractory patients.
